
Tech • AI • Robotics • Game
The planned listing tied to Tibo InShape is not a flotation of the creator himself but of N4 Group, a fast-growing French sports nutrition and equipment company whose model shows how the creator economy is feeding industrial businesses and reshaping IPO narratives.
N4 Group traces its roots to 1999 in Voiron with Fitness Boutique and now operates or distributes 15 brands. Its business spans sports equipment and, increasingly, dietary supplements, the segment driving most of its momentum. The company combines owned brands with licensed creator brands, including Tibo InShape and Sissy Mua, turning audience reach into consumer distribution.
Annual revenue reached €91.1 million, up 31%, while nutrition sales rose 32% over the last year. Operating margin expanded from 11.2% to 16.8%, producing roughly €15 million in operating profit. Those figures place N4 among the more dynamic names in its category and explain why investors are paying attention despite a demanding valuation.
The targeted valuation of about €267 million implies roughly 16.7 times EBITDA. That is above cited peers such as Applied Nutrition, around 10.4 times EBITDA, and Glanbia, around 13 times. Yet N4’s stronger growth profile partly explains the premium, especially as the company sits at the intersection of consumer health and creator-led brand distribution.
The operation is often described as Tibo InShape’s IPO, but the listed asset is N4 Group, not the creator. The company uses the InShape Nutrition brand under a licensing arrangement and pays a brand royalty to the creator. In such models, royalties typically represent a percentage of sales, often in a range of 3% to 15%, while the manufacturer handles production, logistics, e-commerce, retail and advertising.
The most striking indicator is not only revenue growth but the surge in brand royalties paid to creators, which rose by more than 170%. That points to rapidly increasing sales generated by creator-linked products. In effect, N4 has built an industrial platform connected to an audience base estimated at around 35 million followers, giving it a distribution advantage that conventional supplement brands struggle to replicate.
The proposed offering totals around €50 million, but only about €7 million would go to the company. The remaining 86% is secondary stock sold by existing family shareholders, allowing them to diversify part of their wealth. That structure can unsettle retail investors, yet it is common in public listings and does not automatically signal weak prospects if the core business remains sound.
Large investors including Bpifrance, CDC Croissance and BNP Paribas were cited among backers that had already committed more than €20 million during the pre-listing marketing phase. That early demand suggests the secondary-heavy structure did not deter professional investors. For them, the key questions are price, growth durability and business quality rather than whether founders are taking some cash off the table.
Historical data discussed around IPO performance points to a recurring pattern: highly publicized mega-listings often disappoint over the following years, while lesser-known small caps can do better if priced sensibly. One cited study showed small-cap IPOs gaining about 27.7% over two years and 85.7% over five, far better than larger listings in the same sample. The edge often comes from lower initial valuations and lower market attention.
N4 illustrates a growing model in which creators do not need to own factories or logistics to capture value. Instead, industrial groups can plug creator brands into existing production and retail systems, while creators monetize through royalties and audience leverage. That raises the prospect of future listed companies designed explicitly as diversified bets on the creator economy, though such vehicles remain rare in Europe.
The N4 Group deal highlights how creator influence is being converted into scalable consumer businesses, with public markets beginning to price that shift. The main question is not whether creator-backed brands can grow, but whether investors are buying that growth at the right valuation.
Ask a question